Gastrointestinal symptoms under opioid therapy: A prospective comparison of oral sustained‐release hydromorphone, transdermal fentanyl, and transdermal buprenorphine

Abstract

Gastrointestinal symptoms of cancer pain patients undergoing an opioid therapy are related to multifactorial causes. Transdermal opioids showed no benefit over oral controlled-release hydromorphone with regard to gastrointestinal symptoms. The conversion ratios for transdermal fentanyl, transdermal buprenorphine, and oral hydromorphone did not accord to the literature, because of differing occurrences of opioid tolerance after long-term therapy.